Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 2:4:100118.
doi: 10.1016/j.jtauto.2021.100118. eCollection 2021.

Diagnosis and treatment of eosinophilic myocarditis

Affiliations
Review

Diagnosis and treatment of eosinophilic myocarditis

Zezhong Zhong et al. J Transl Autoimmun. .

Abstract

Eosinophilic myocarditis is a type of inflammatory cardiomyopathy characterized by eosinophilic infiltration into myocardial tissue. The accurate myocarditis incidence rate is difficult to determine because of the clinical limitations of an endomyocardial biopsy. The primary pathogenesis of eosinophilic myocarditis is the release of related substances by eosinophils, leading to cell membrane damage and cell destruction. However, evidence suggests that specific genes play a role in myocarditis development.As CMR imaging availability increases, the diagnosis rate of eosinophilic myocarditis will increase. The diagnosis of myocarditis mainly depends on an endocardial biopsy. Glucocorticoids can relieve patients' symptoms, but the early use of steroids may prevent intermediate disease stage development (i.e., thrombonecrosis and fibrosis with wall thrombosis). Anticoagulant therapy may also affect disease development. In addition to routine follow-up, a regular myocardial biopsy should be considered for discharged patients, if possible.

Keywords: ANCA, anti-neutrophil cytoplasmic antibody; CEL, chronic eosinophilic leukemia.; CMR, cardiac magnetic resonance; Cardiac magnetic resonance; EAM, experimental autoimmune myocarditis; ECG, electrocardiogram; ECP, eosinophilic cationic protein; EGE, early gadolinium enhancement, LGE, late gadolinium enhancement; EGPA, eosinophilic granulomatosis with polyangiitis; EMB, endomyocardial biopsy; Endomyocardial biopsy; Eosinophilic myocarditis; FIP1L1-PDGFRA, FIP1-like1-platelet-derived growth factor receptor α; Glucocorticoids; HES, hypereosinophilic syndrome; IFNγ, interferon gamma.

PubMed Disclaimer

Conflict of interest statement

None.

Similar articles

Cited by

References

    1. Löffler W. Endocarditis parietalis fibroplastica mit Bluteosinophilie. Schweiz. Med. Wochenschr. 1936;65:817–820. - PubMed
    1. Gore I., Saphir O. Myocarditis; a classification of 1402 cases. Am. Heart J. 1947;34:827–830. doi: 10.1016/0002-8703(47)90147-6. - DOI - PubMed
    1. Basso C., Calabrese F., Corrado D., Thiene G. Postmortem diagnosis in sudden cardiac death victims: Macroscopic, microscopic and molecular findings. Cardiovasc. Res. 2001;50:290–300. doi: 10.1016/s0008-6363(01)00261-9. - DOI - PMC - PubMed
    1. Mason J.W., O'Connell J.B., Herskowitz A., Rose N.R., McManus B.M., Billingham M.E., Moon T.E. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis Treatment Trial Investigators. N. Engl. J. Med. 1995;333:269–275. doi: 10.1056/NEJM199508033330501. - DOI - PubMed
    1. Felker G.M., Hu W., Hare J.M., Hruban R.H., Baughman K.L., Kasper E.K. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltim.) 1999;78:270–283. doi: 10.1097/00005792-199907000-00005. - DOI - PubMed

LinkOut - more resources